Transcriptomic hepatotoxicity signature of chlorpromazine after short- And long-term exposure in primary human sandwich cultures

Drug Metabolism and Disposition

Volumn 41, Issue 10, 2013, Pages 1835-1842

  Parmentier, Céline ^a   Truisi, Germaine L ^b,e   Moenks, Konrad ^c   Stanzel, Sven ^d   Lukas, Arno ^c   Kopp Schneider, Annette ^d   Alexandre, Eliane ^a   Hewitt, Philip G ^b   Mueller, Stefan O ^b,e   Richert, Lysiane ^a,f  

^a KaLy Cell   (France)

^b Merck Serono GmbH   (Germany)

^c Emergentec Biodevelopment GmbH   (Austria)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^f UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; MESSENGER RNA;

ADULT; AGED; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CHOLESTASIS; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; GENE EXPRESSION; GENE NUMBER; HEPATITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER NECROSIS; LIVER TOXICITY; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; STEATOSIS; TRANSCRIPTOMICS;

AGED; CELLS, CULTURED; CHLORPROMAZINE; DRUG-INDUCED LIVER INJURY; FEMALE; HEPATOCYTES; HUMANS; INFLAMMATION; LIVER; MALE; MIDDLE AGED; TRANSCRIPTOME;

EID: 84884689040     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.052415     Document Type: Article

References (58)

1. Abadie-Viollon C, Martin H, Blanchard N, Pekthong D, Bachellier P, Mantion G, Heyd B, Schuler F, Coassolo P, and Alexandre E, et al. (2010) Follow-up to the pre-validation of a harmonised protocol for assessment of CYP induction responses in freshly isolated and cryopreserved human hepatocytes with respect to culture format, treatment, positive reference inducers and incubation conditions. Toxicol In Vitro 24:346-356.
2. Abernathy CO, Lukacs L, and Zimmerman HJ (1977) Adverse effects of chlorpromazine metabolites on isolated hepatocytes. Proc Soc Exp Biol Med 155:474-478. (Pubitemid 8204916)
3. Binda D, Lasserre-Bigot D, Bonet A, Thomassin M, Come MP, Guinchard C, Bars R, Jacqueson A, and Richert L (2003) Time course of cytochromes P450 decline during rat hepatocyte isolation and culture: effect of L-NAME. Toxicol In Vitro 17:59-67. (Pubitemid 36106492)
4. Blanchard N, Alexandre E, Abadie C, Lavé T, Heyd B, Mantion G, Jaeck D, Richert L, and Coassolo P (2005) Comparison of clearance predictions using primary cultures and suspensions of human hepatocytes. Xenobiotica 35:1-15. (Pubitemid 40459213)
5. Boelsterli UA, Bouis P, and Donatsch P (1987) Relative cytotoxicity of psychotropic drugs in cultured rat hepatocytes. Cell Biol Toxicol 3:231-250. (Pubitemid 18017448)
6. Boess F, Kamber M, Romer S, Gasser R, Muller D, Albertini S, and Suter L (2003) Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems. Toxicol Sci 73:386-402. (Pubitemid 36701742)
7. Bolstad BM, Irizarry RA, Astrand M, and Speed TP (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19:185-193. (Pubitemid 36181903)
8. Borges NC, Rezende VM, Santana JM, Moreira RP, Moreira RF, Moreno P, Borges DC, Donato JL, and Moreno RA (2011) Chlorpromazine quantification in human plasma by UPLC-electrospray ionization tandem mass spectrometry. Application to a comparative pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 879:3728-3734.
9. Brind AM (2007) Drugs that damage the liver. Medicine 35:26-30.
10. Buchweitz JP, Ganey PE, Bursian SJ, and Roth RA (2002) Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy? J Pharmacol Exp Ther 300:460-467.
11. Chetty M, Miller R, and Moodley SV (1994) Smoking and body weight influence the clearance of chlorpromazine. Eur J Clin Pharmacol 46:523-526. (Pubitemid 24247927)
12. de Abajo FJ, Montero D, Madurga M, and García Rodríguez LA (2004) Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 58:71-80. (Pubitemid 38901470)
13. De Bruyn T, Ye Z-W, Peeters A, Sahi J, Baes M, Augustijns PF, and Annaert PP (2011) Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes. Eur J Pharm Sci 43:297-307.
14. Demeilliers C, Jacquemin E, Barbu V, Mergey M, Paye F, Fouassier L, Chignard N, Housset C, and Lomri NE (2006) Altered hepatobiliary gene expressions in PFIC1: ATP8B1 gene defect is associated with CFTR downregulation. Hepatology 43:1125-1134. (Pubitemid 43724637)
15. Foster JA, Houston JB, and Hallifax D (2011) Comparison of intrinsic clearances in human liver microsomes and suspended hepatocytes from the same donor livers: clearance-dependent relationship and implications for prediction of in vivo clearance. Xenobiotica 41:124-136.
16. Gerets HH, Tilmant K, Gerin B, Chanteux H, Depelchin BO, Dhalluin S, and Atienzar FA (2012) Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol 28:69-87.
17. Gómez-Lechón MJ, Castell JV, and Donato MT (2010) The use of hepatocytes to investigate drug toxicity. Methods Mol Biol 640:389-415.
18. Goyak KM, Johnson MC, Strom SC, and Omiecinski CJ (2008) Expression profiling of interindividual variability following xenobiotic exposures in primary human hepatocyte cultures. Toxicol Appl Pharmacol 231:216-224.
19. Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, and Skonberg C, et al. (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159-234.
20. Hinson JA, Roberts DW, and James LP (2010) Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol (196):369-405.
21. Horikawa M, Kato Y, Tyson CA, and Sugiyama Y (2003) Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans. Drug Metab Pharmacokinet 18:16-22.
22. Jansen PLM (2004) Non-alcoholic steatohepatitis. Eur J Gastroenterol Hepatol 16:1079-1085.
23. Jones SA, Horiuchi S, Topley N, Yamamoto N, and Fuller GM (2001) The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 15:43-58. (Pubitemid 32061655)
24. Larrey D and Pageaux GP (1997) Genetic predisposition to drug-induced hepatotoxicity. J Hepatol 26 (Suppl 2):12-21.
25. Lauer B, Tuschl G, Kling M, and Mueller SO (2009) Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact 179:17-24.
26. Lecluyse EL and Alexandre E (2010) Isolation and culture of primary hepatocytes from resected human liver tissue. Methods Mol Biol 640:57-82.
27. Lee J and Boyer JL (2000) Molecular alterations in hepatocyte transport mechanisms in acquired cholestatic liver disorders. Semin Liver Dis 20:373-384.
28. Lee WM (2003) Drug-induced hepatotoxicity. N Engl J Med 349:474-485.
29. Li AP (2009) Metabolism Comparative Cytotoxicity Assay (MCCA) and Cytotoxic Metabolic Pathway Identification Assay (CMPIA) with cryopreserved human hepatocytes for the evaluation of metabolism-based cytotoxicity in vitro: proof-of-concept study with aflatoxin B1. Chem Biol Interact 179:4-8.
30. Li W, Liang X, Kellendonk C, Poli V, and Taub R (2002) STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration. J Biol Chem 277:28411-28417. (Pubitemid 41079264)
31. Liguori MJ, Anderson MG, Bukofzer S, McKim J, Pregenzer JF, Retief J, Spear BB, and Waring JF (2005) Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. Hepatology 41:177-186. (Pubitemid 40066396)
32. Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, Mahieu P, Malaise M, De Groote D, and Louis R, et al. (1998) Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 113:401-406. (Pubitemid 28410565)
33. Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, and Ribadeneira MD, et al. (2003) Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31:421-431. (Pubitemid 36378519)
34. Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, and Schmid M (1994) Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology 20:1437-1441.
35. Mueller D, Müller-Vieira U, Biemel KM, Tascher G, Nüssler AK, and Noor F (2012) Biotransformation of diclofenac and effects on the metabolome of primary human hepatocytes upon repeated dose exposure. Eur J Pharm Sci 45:716-724.
36. Pantuck EJ, Pantuck CB, Anderson KE, Conney AH, and Kappas A (1982) Cigarette smoking and chlorpromazine disposition and actions. Clin Pharmacol Ther 31:533-538. (Pubitemid 13097399)
37. Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, and Artursson P (2008) Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). J Med Chem 51:3275-3287. (Pubitemid 351821886)
38. Regal RE, Billi JE, and Glazer HM (1987) Phenothiazine-induced cholestatic jaundice. Clin Pharm 6:787-794. (Pubitemid 17153596)
39. Richert L, Alexandre E, Lloyd T, Orr S, Viollon-Abadie C, Patel R, Kingston S, Berry D, Dennison A, and Heyd B, et al. (2004) Tissue collection, transport and isolation procedures required to optimize human hepatocyte isolation from waste liver surgical resections. A multilaboratory study. Liver Int 24:371-378. (Pubitemid 39162077)
40. Richert L, Binda D, Hamilton G, Viollon-Abadie C, Alexandre E, Bigot-Lasserre D, Bars R, Coassolo P, and LeCluyse E (2002) Evaluation of the effect of culture configuration on morphology, survival time, antioxidant status and metabolic capacities of cultured rat hepatocytes. Toxicol In Vitro 16:89-99. (Pubitemid 34112641)
41. Richert L, Lamboley C, Viollon-Abadie C, Grass P, Hartmann N, Laurent S, Heyd B, Mantion G, Chibout SD, and Staedtler F (2003) Effects of clofibric acid on mRNA expression profiles in primary cultures of rat, mouse and human hepatocytes. Toxicol Appl Pharmacol 191:130-146. (Pubitemid 36999849)
42. Richert L, Liguori MJ, Abadie C, Heyd B, Mantion G, Halkic N, and Waring JF (2006) Gene expression in human hepatocytes in suspension after isolation is similar to the liver of origin, is not affected by hepatocyte cold storage and cryopreservation, but is strongly changed after hepatocyte plating. Drug Metab Dispos 34:870-879.
43. Richert L, Tuschl G, Abadie C, Blanchard N, Pekthong D, Mantion G,Weber JC, and Mueller SO (2009) Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol 235:86-96.
44. Richert L, Tuschl G, Viollon-Abadie C, Blanchard N, Bonet A, Heyd B, Halkic N, Wimmer E, Dolgos H, and Mueller SO (2008) Species differences in the response of liver drug-metabolizing enzymes to (S)-4-O-tolylsulfanyl-2-(4- trifluormethyl-phenoxy)-butyric acid (EMD 392949) in vivo and in vitro. Drug Metab Dispos 36: 702-714. (Pubitemid 351468377)
45. Rogue A, Lambert C, Spire C, Claude N, and Guillouzo A (2012) Interindividual variability in gene expression profiles in human hepatocytes and comparison with HepaRG cells. Drug Metab Dispos 40:151-158.
46. Roth RA, Luyendyk JP, Maddox JF, and Ganey PE (2003) Inflammation and drug idiosyncrasy - is there a connection? J Pharmacol Exp Ther 307:1-8. (Pubitemid 37151885)
47. Soars MG, McGinnity DF, Grime K, and Riley RJ (2007) The pivotal role of hepatocytes in drug discovery. Chem Biol Interact 168:2-15. (Pubitemid 46661937)
48. Tavoloni N and Boyer JL (1980) Relationship between hepatic metabolism of chlorpromazine and cholestatic effects in the isolated perfused rat liver. J Pharmacol Exp Ther 214:269-274. (Pubitemid 10049034)
49. Tsao SC, Sawada Y, Iga T, and Hanano M (1983) Effect of chlorpromazine on hepatic transport of indocyanine green in rats. Biochem Pharmacol 32:1105-1112. (Pubitemid 13084020)
50. Tuschl G, Hrach J, Walter Y, Hewitt PG, and Mueller SO (2009) Serum-free collagen sandwich cultures of adult rat hepatocytes maintain liver-like properties long term: a valuable model for in vitro toxicity and drug-drug interaction studies. Chem Biol Interact 181:124-137.
51. Tuschl G, Lauer B, and Mueller SO (2008) Primary hepatocytes as a model to analyze species-specific toxicity and drug metabolism. Expert Opin Drug Metab Toxicol 4:855-870.
52. van Pelt JF, Verslype C, Crabbé T, Zaman Z, and Fevery J (2003) Primary human hepatocytes are protected against prolonged and repeated exposure to ethanol by silibinin-dihemisuccinate. Alcohol Alcohol 38:411-414. (Pubitemid 37063380)
53. Wójcikowski J, Boksa J, and Daniel WA (2010) Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver - A comparison with other phenothiazines. Biochem Pharmacol 80:1252-1259.
54. Yeung PK, Hubbard JW, Korchinski ED, and Midha KK (1993) Pharmacokinetics of chlorpromazine and key metabolites. Eur J Clin Pharmacol 45:563-569. (Pubitemid 24036937)
55. Yoshii K, Kobayashi K, Tsumuji M, Tani M, Shimada N, and Chiba K (2000) Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Sci 67:175-184. (Pubitemid 30414484)
56. Zhang S, Tong W, Zheng B, Susanto TA, Xia L, Zhang C, Ananthanarayanan A, Tuo X, Sakban RB, and Jia R, et al. (2011) A robust high-throughput sandwich cell-based drug screening platform. Biomaterials 32:1229-1241.
57. Zhao P, Kunze KL, and Lee CA (2005) Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metab Dispos 33:853-861. (Pubitemid 40686640)
58. Zollner G, Fickert P, Zenz R, Fuchsbichler A, Stumptner C, Kenner L, Ferenci P, Stauber RE, Krejs GJ, and Denk H, et al. (2001) Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 33:633-646. (Pubitemid 32185226)